A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
Non-interventional, multi-center, long-term follow-up study of subjects previously treated with a Mustang Bio CAR-T cell investigational product in a Mustang Bio sponsored clinical study. Subjects who enroll will be monitored for a total of up to 15 years from the time of their last investigational product infusion.
Study Type
OBSERVATIONAL
Enrollment
3
No investigational product will be administered.
No investigational product will be administered.
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Rochester Medical Center
Rochester, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Adverse events (AEs)
Incidence and characterization of adverse events (AEs) related to prior treatment with a Mustang Bio CAR-T cell investigational product received in a Mustang Bio sponsored clinical study.
Time frame: Up to a total of 15 years
Replication competent lentivirus (RCL)
Detection of replication competent lentivirus (RCL).
Time frame: Up to a total of 15 years
Survival
Overall Survival.
Time frame: Up to a total of 15 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.